High-dose mesalazine treatment for ulcerative colitis patients who relapse under low-dose maintenance therapy.

[1]  B. Feagan,et al.  Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. , 2016, The Cochrane database of systematic reviews.

[2]  R. D'Incà,et al.  Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: A prospective, multicenter study , 2012, Inflammatory bowel diseases.

[3]  J. Reguła,et al.  Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. , 2009, Gastroenterology.

[4]  I. Gorelov,et al.  Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial , 2008, Gut.

[5]  R. Burakoff,et al.  The role of mesalamine in the treatment of ulcerative colitis , 2007, Therapeutics and clinical risk management.

[6]  M. Kamm,et al.  MMX Multi Matrix System® mesalazine for the induction of remission in patients with mild‐to‐moderate ulcerative colitis: a combined analysis of two randomized, double‐blind, placebo‐controlled trials , 2007, Alimentary pharmacology & therapeutics.

[7]  F. Ajayi,et al.  Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial , 2005, The American Journal of Gastroenterology.

[8]  P. Marteau,et al.  An unusual cause of soft tissue infection , 2005, Gut.

[9]  S. Katz.  Update in medical therapy of ulcerative colitis: a practical approach. , 2002, Journal of clinical gastroenterology.

[10]  G. May,et al.  Sulfasalazine Revisited , 1993, Annals of Internal Medicine.

[11]  L. Sutherland,et al.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. , 1987, Gastroenterology.

[12]  S. Hansen,et al.  5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. , 1982, Gastroenterology.

[13]  M. Kamm,et al.  Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  M. Kamm,et al.  Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. , 2007, Gastroenterology.

[15]  S. Hanauer,et al.  Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. , 2007, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[16]  J. Macdonald,et al.  Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. , 2003, The Cochrane database of systematic reviews.